Xiamen Kingdomway Group Company(002626) : at present, intermediate P2 has not been commercially produced

E company news, Xiamen Kingdomway Group Company(002626) ( Xiamen Kingdomway Group Company(002626) ) announced the abnormal fluctuation of stock trading on March 6. At present, the company has no orders for intermediate P2, and there is no indication that orders can be obtained in the future. If it is unable to sell intermediate P2 directly or indirectly to Pfizer and its related companies in the industrial chain, or to the manufacturers of related generic drugs (if any), It may lead to the termination of the project investment plan, partial termination, change of the investment plan and the risk that the income does not meet the expectation. At present, intermediate P2 has not been commercially produced in the company and is not expected to have a significant impact on the company’s performance in 2022.